Journal article
Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner
PJ Clark, AJ Thompson, DM Vock, LE Kratz, AA Tolun, AJ Muir, JG Mchutchison, M Subramanian, DM Millington, RI Kelley, K Patel
Hepatology | WILEY | Published : 2012
DOI: 10.1002/hep.25631
Abstract
Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference results in the frequently observed, genotype-dependent clinical sequelae of hypocholesterolemia, hepatic steatosis, and insulin resistance (IR) remains incompletely understood. Hypocholesterolemia typically resolves after sustained viral response (SVR), implicating viral interference in host lipid metabolism. Using a targeted cholesterol metabolomic platform we evaluated paired HCV genotype 2 (G2) and G3 patient sera for changes in in vivo HCV sterol pathway metabolites. We compared HCV genotypic differences in baseline metabolites and following antiviral treatment to assess..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
Funded by the Duke Clinical Research Institute. Drs. Clark and Thompson received funding from the Duke Clinical Research Institute, the Richard Boebel Family Fund, the National Health and Medical Research Council of Australia (P.J.C.: APP1017139; A.J.T.: APP567057) and the Gastroenterological Society of Australia. Dr. Thompson received funding from the Royal Australian College of Physicians. Dr. Clark received funding from American Association for the Study of Liver Diseases/LIFER Clinical and Translational Research Fellowship in Liver Diseases Award and the National Centre in HIV Epidemiology and Clinical Research (now the Kirby Institute for Infection and Immunity in Society), University of New South Wales, Australia.Potential conflict of interest: Dr. Muir consults for and received grants from Merck, Vertex, Bristol-Myers Squibb, GlaxoSmithKline, and Scynexis. He consults for Achillion and received grants from Gilead, Pfizer, and Abbott.